Effect of the Peroxisome Proliferator-Activated Receptor- 2 Pro12Ala Variant on Obesity, Glucose Homeostasis, and Blood Pressure in Members of Familial Type 2 Diabetic Kindreds

2001 ◽  
Vol 86 (2) ◽  
pp. 536-541 ◽  
Author(s):  
S. J. Hasstedt
Keyword(s):  
Blood Pressure ◽  
Glucose Homeostasis ◽  
Peroxisome Proliferator ◽  
Peroxisome Proliferator Activated Receptor ◽  
Familial Type ◽  
Type 2 Diabetic

scholarly journals PPARγAgonists: Blood Pressure and Edema

PPAR Research ◽  
2010 ◽  
Vol 2010 ◽  
pp. 1-5 ◽  
Author(s):  
Bonnie L. Blazer-Yost
Keyword(s):  
Blood Pressure ◽  
Fluid Retention ◽  
Peroxisome Proliferator ◽  
Positive Aspect ◽  
Drug Induced ◽  
Peroxisome Proliferator Activated Receptor ◽  
Alternative Pathways ◽  
Blood Pressure Data ◽  
Induced Changes

Peroxisome proliferator activated receptorγ(PPARγ) agonists are widely used in the treatment of type 2 diabetes. Side effects of drug treatment include both fluid retention and a lowering of blood pressure. Data from animal and human studies suggest that these effects arise, at least in part, from drug-induced changes in the kidney. In order to capitalize on the positive aspect (lowering of blood pressure) and exclude the negative one (fluid retention), it is necessary to understand the mechanisms of action underlying each of the effects. When interpreted with known physiological principles, current hypotheses regarding potential mechanisms produce enigmas that are difficult to resolve. This paper is a summary of the current understanding of PPARγagonist effects on both blood pressure and fluid retention from a renal perspective and concludes with the newest studies that suggest alternative pathways within the kidney that could contribute to the observed drug-induced effects.

Sign in / Sign up

Export Citation Format

Share Document